Compare JCE & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | JCE | NMRA |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.2M | 302.0M |
| IPO Year | 2007 | 2023 |
| Metric | JCE | NMRA |
|---|---|---|
| Price | $16.96 | $0.55 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $6.14 |
| AVG Volume (30 Days) | 23.2K | ★ 1.5M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.99 | $0.63 |
| 52 Week High | $17.45 | $3.65 |
| Indicator | JCE | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 50.17 | 20.52 |
| Support Level | $16.75 | N/A |
| Resistance Level | $17.11 | $1.74 |
| Average True Range (ATR) | 0.27 | 0.09 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 62.05 | 2.13 |
Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the S&P 500 Index. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.